Abbott to Acquire Exact Sciences for $105/Share

Abbotts acquisition of Exact Sciences for $105 per share, expected to close in Q2 2023, marks a significant expansion in the diagnostics market. Exact Sciences strong Q3 performance and raised revenue forecast contributed to the high valuation, benefiting shareholders. The deal aligns with industry trends of major companies investing in innovative cancer treatments and screening technologies. Oppenheimer analysts noted the financing structures importance for investor appeal. Following the announcement, Exact Sciences shares surged 17%, while Abbotts closed down 2% despite a 10% year-to-date gain.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.